PCA
RCUS icon

Personal Capital Advisors’s Arcus Biosciences RCUS Stock Holding History

Personal Capital Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,395
Closed -$246K – 502
2022
Q3 		$246K Hold
9,395
– – ﹤0.01% 403
2022
Q2 		$238K Hold
9,395
– – ﹤0.01% 396
2022
Q1 		$297K Hold
9,395
– – ﹤0.01% 394
2021
Q4 		$380K Hold
9,395
– – ﹤0.01% 384
2021
Q3 		$328K Hold
9,395
– – ﹤0.01% 385
2021
Q2 		$258K Hold
9,395
– – ﹤0.01% 421
2021
Q1 		$264K Hold
9,395
– – ﹤0.01% 416
2020
Q4 		$244K Buy
+9,395
New +$227K ﹤0.01% 417
2020
Q3 		– Sell
-9,395
Closed -$232K – 422
2020
Q2 		$232K Buy
+9,395
New +$254K ﹤0.01% 329

Other funds holding RCUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Personal Capital Advisors's RCUS Position: Q4 2022 in Review

Personal Capital Advisors sold out of Arcus Biosciences (RCUS) in Q4 2022, closing a stake of 9,395 shares — an estimated $246K sold.

Personal Capital Advisors first reported a position in RCUS in Q2 2020 and held it in 9 quarters. The position peaked at $380K in Q4 2021. 200 funds tracked by Wall St. Rank hold RCUS as of Q4 2022.

  • Personal Capital Advisors reported no remaining Arcus Biosciences position as of Q4 2022 after selling out during the quarter.
  • Personal Capital Advisors sold 9,395 Arcus Biosciences shares in Q4 2022, an estimated $246K.
  • Personal Capital Advisors first reported a position in Arcus Biosciences in Q2 2020 and held it in 9 quarters.
  • Personal Capital Advisors's Arcus Biosciences position peaked at $380K in Q4 2021.
  • 200 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.